ClinicalTrials.gg
CompletedNCT01081769PROSIPALUpdated Feb 18, 2015Results posted

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics

A Phase 3 interventional study of paliperidone palmitate injection and oral antipsychotics in Schizophrenia, sponsored by Janssen-Cilag International NV. Completed at 99 sites in 25 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-02-18.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
769
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
7th of 115
769 · median 178
Started
2010
with 7 others
Phase 3
41 of 115
none open now
Registered
55th of 115
by date
Lead sponsor
6 of 115
Janssen-Cilag International NV

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 7th largest by enrollment, is one of 8 that started in 2010, is one of 41 in phase 3, and was the 55th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered antipsychotics in monotherapy over 24 months in the treatment of recently diagnosed (1-5 years since diagnosis) schizophrenia.

Read the detailed description

This is a randomized (study drug assigned by chance), open-label (both physician and patient know the name of the assigned drug), rater-blinded (the person who assesses the condition of the patient does not know the name of the assigned drug), active-controlled, parallel-group, multicenter, prospective international study of paliperidone palmitate versus treatment as usual with oral antipsychotic agents in monotherapy in the prevention of relapse (return of symptoms). Patients who have been recently diagnosed with schizophrenia (within 5 years) and are suffering from a schizophrenic relapse (return of symptoms of schizophrenia) will be enrolled. This study consists of a 2-week initial acute oral treatment phase, followed by a treatment phase (core phase) until relapse or up to maximally 24 months, whichever comes first. Prior to a 2-week oral treatment phase, patients will be randomly (by chance) assigned in a 1:1 ratio to receive treatment with paliperidone palmitate injection (once-monthly) or oral antipsychotic medication (daily). Patients randomized to paliperidone palmitate will first receive oral paliperidone ER once daily for 2 weeks followed by paliperidone palmitate injections at a dose of 150 mg eq. on Day 1, 100 mg eq. on Day 8 both in the deltoid muscle and 75 mg eq. on Day 38 and doses in a dose range of 25 to 150 mg eq. in either the deltoid or the gluteal muscle thereafter. Patients randomized to oral comparator arm will receive oral antipsychotics (haloperidol, paliperidone ER, risperidone, olanzapine, quetiapine or aripiprazole) as per investigator discretion and prescribed according to the label. Total treatment duration is maximally 24 months. During the 24 month treatment phase, investigators will be allowed to flexibly decrease or increase the dose of paliperidone palmitate with one dose level in the range of 25 to 150 mg eq. or the oral antipsychotic in the respective locally approved dose range, all according to the patient's clinical needs. The primary endpoint of the 24-month treatment phase will be the time to relapse. Safety will be monitored by evaluating Adverse Events (AEs), rating of extrapyramidal symptoms (symptoms like abnormal muscle movements, abnormal movements of the tongue or jaw, slow or sustained muscle contractions, muscle spasms, shaking, abnormal movements of the eyes, involuntary muscle contractions, slow movements, or restlessness), vital signs measurements (including heart rate and blood pressure), body weight and physical examination findings. A urine pregnancy test will be performed in females of childbearing potential. Adverse events (unintended, but not necessarily unexpected, results of therapy that can be unpleasant or dangerous), associated concomitant medications, and symptoms of relapse will be recorded as needed.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • paliperidone palmitate
  • Invega
  • Intramuscular injection
  • Oral antipsychotics
  • Relapse
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been meeting the diagnostic criteria for schizophrenia for 1 to 5 years before screening, and have a history of treatment with antipsychotics
  • Have a history of two or more relapses requiring psychiatric hospitalization in the preceding 24 months, which may include the current acute episode
  • Experiencing at screening an acute schizophrenic episode with a Positive And Negative Syndrome Scale (PANSS) total score at screening between 70 and 120, inclusive
  • Be healthy on the basis of physical examination, medical history and vital signs performed at screening
  • Woman must be (for at least 1 year) or surgically sterile or abstinent or be practicing an effective method of , must agree to continue to use the same method of contraception throughout the study and must have a negative urine pregnancy test at screening
  • be able to fill out questionnaires
  • Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Patients that have never been treated with antipsychotics before
  • Treatment resistant patient and/or currently (i.within the last 3 months) treated with clozapine
  • Substance dependence within 6 months prior to entry and current intravenous drug use or abuse
  • allergies, , or intolerance to risperidone or paliperidone or
  • treatment with a long-acting injectable antipsychotic within three injection cycles prior to screening
  • newly started psychotherapy program within the two months preceding the treatment phase baseline
  • evidence of hepatic, renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances in the past 6 months (as determined by medical history, clinical laboratory or results, or physical examination) that would increase the risk associated with taking study medication or would confound the interpretation of the study
  • history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome
  • involuntarily hospitalized patient
  • pregnant or breast-feeding females
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
769 participants (actual)

Study arms

  • Experimental
    Paliperidone Palmitate

    paliperidone palmitate injection with 150 mg equivalent on Day 1 100 mg equivalent on Day 8 75 mg equivalent on Day 38 and flexible dosing with 25 50 75 100 or 150 mg equivalent once monthly thereafter

    Drug: paliperidone palmitate injection

  • Active comparator
    Oral Antipsychotics

    oral antipsychotics daily treatment according to local label for maximally 24 months

    Drug: oral antipsychotics

Interventions

  • injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter

  • daily treatment according to local label for maximally 24 months

06

What researchers measure

Primary outcomes

  1. Time to First Relapse Event

    Number of days from baseline (day 1 of core phase) to relapse as evaluated according the Csernansky criteria. A patient was considered to have relapsed if they met one or more of the following criteria: (1) psychiatric hospitalization; (2) an increase in the level of psychiatric care and an increase of 25 percent (%) from baseline in the Positive And Negative Syndrome Score (PANSS) total score (or an increase of 10 points if the baseline score was 40 or less); (3) deliberate self-injury; (4) suicidal or homicidal ideation that was clinically significant in the investigator's judgment; (5) violent behavior resulting in clinically significant injury to another person or property damage; (6) substantial clinical deterioration, defined as a change score of 6 ("much worse") or 7 ("very much worse") on the Clinical Global Impressions Scale (CGI-C); and/or (7) the required dose of the antipsychotic exceeds the maximum approved dose.

    Time frame: from baseline (Day 1 of core phase) up to maximally 24 months.

  2. Number of Participants With a Relapse Event

    Number of participants with a relapse event with relapses evaluated according the Csernansky criteria. A patient was considered to have relapsed if they met one or more of the following criteria: (1) psychiatric hospitalization; (2) an increase in the level of psychiatric care and an increase of 25% from baseline in the PANSS total score (or an increase of 10 points if the baseline score was 40 or less); (3) deliberate self-injury; (4) suicidal or homicidal ideation that was clinically significant in the investigator's judgment; (5) violent behavior resulting in clinically significant injury to another person or property damage; (6) substantial clinical deterioration, defined as a change score of 6 ("much worse") or 7 ("very much worse") on the Clinical Global Impressions Scale (CGI-C); and/or (7) the required dose of the antipsychotic exceeds the maximum approved dose.

    Time frame: from baseline (Day 1 of core phase) up to maximally 24 months

Secondary outcomes

  1. Percentage of Treatment Responders

    The proportion of patients achieving a treatment response, defined as a ≥30% decrease (i.e., improvement) in Positive and Negative Syndrome Scale (PANSS) total score from baseline to endpoint. The PANSS is a 30-item scale (Range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate increased severity of schizophrenia symptoms.

    Time frame: from baseline (day 1 of core phase) up to maximally 24 months

  2. Change From Baseline in PANSS Total Score

    Change from baseline in the PANSS: The PANSS is a 30-item scale (Range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.

    Time frame: Baseline, day 8, month 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, 24

  3. Change From Baseline in PANSS Subscale Score

    Change from baseline in positive symptom, negative symptom and general psychopathology subscales of the PANSS scale. The PANSS scale is designed to assess symptoms of schizophrenia by means of the 30-items. The PANSS scale provides subscores for 3 subscales, that is, the positive symptoms subscale (7 items, range 7-49), the negative symptoms subscale (7 items, range 7-49), and the general psychopathology subscale (16 items, range 16-112). Each item of the scale is to be scored on a scale of 1 (absent) to 7 (extreme). Higher scores indicate higher severity of schizophrenia symptoms.

    Time frame: Baseline (day 1 of core phase), day 8, month 12, 24

  4. Change From Baseline in PANSS Marder Factor Scores

    Change from baseline in schizophrenia symptoms were assessed through the following PANSS factor scores as described by Marder: (1) positive symptoms (range 8-56): sum of delusions, hallucinatory behavior, grandiosity, suspiciousness, stereotyped thinking, somatic concern, unusual thought content, lack of judgment and insight; (2) negative symptoms (range 7-49): sum of blunted affect, emotional withdrawal, poor rapport, passive social withdrawal, lack of spontaneity, motor retardation, and active social avoidance; (3) disorganized thoughts (range 7-49): sum of conceptual disorganization, difficulty in abstract thinking, mannerisms and posturing, disorientation, poor attention, disturbance of volition, and preoccupation; (4) uncontrolled hostility/excitement (range 4-28): sum of excitement, hostility, uncooperativeness and poor impulse control; (5) anxiety/depression (range 4-28): sum of anxiety, guilt feelings, tension, and depression. Higher scores indicate higher severity of symptoms

    Time frame: Baseline (day 1 of core phase), day 8, month 12 and 24

  5. Change From Baseline in Clinical Global Impression Severity (CGI-S) Score

    The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global clinical assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate higher impression of illness severity.

    Time frame: Baseline (day 1 of core phase), day 8, month 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, 24

  6. Clinical Global Impression-Change (CGI-C)

    The Clinical Global Impression-Change (CGI-C) rating scale is used to rate the change in severity of the patient's illness compared to baseline (day 1 of core phase) on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Month 24 and endpoint

  7. Changes From Baseline in Personal and Social Performance (PSP) Total Score

    The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

    Time frame: baseline (day 1 of core phase), month 1, 3, 6, 9, 12, 15, 18, 21 and 24

  8. Change From Baseline in Short Form-36 Health Survey (SF-36)

    The Short Form-36 Health Survey (SF-36) is a measure of Participant-reported health status. It is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Two summary scale scores are computed based on weighted combinations of the 8 subscale scores: the Physical Component Summary and the Mental Component Summary. Each summary scale score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status.

    Time frame: baseline (day 1 of core phase), month 6, 12 and 24

  9. Change From Baseline in EuroQol 5-Dimensional Questionnaire (EQ-5D) VAS Score

    The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analog scale, with 0 representing the worst imaginable health state and 100 representing the best imaginable health state. The EQ VAS is used as a quantitative measure of health outcome as judged by the individual respondent.

    Time frame: baseline (day 1 of core phase), month 6, 12 and 24

  10. Change From Baseline in EuroQol 5-Dimensional Questionnaire (EQ-5D) Index Score

    The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. A higher score indicates an improvement in health in the Health Status Index.

    Time frame: baseline (day 1 of core phase), month 6, 12 and 24

  11. Change From Baseline in Subjective Well-Being Under Neuroleptics-Short Form (SWN-S) Total Score

    The SWN-S is a patient self-rated scale developed to measure the subjective well-being for the previous 7 days of a patient under neuroleptic treatment. The SWN-S consists of 20 items (each item is rated from 1=not at all to 6=very much). The total score ranges from 20 to 120 with higher score indicating greater subjective well-being.

    Time frame: baseline (day 1 of core phase), month 6, 12 and 24

  12. Change From Baseline in Patient's Treatment Satisfaction

    Patient's satisfaction with medication was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM is divided into 4 subscales (effectiveness, side effects, convenience, and global satisfaction), with the value of each subscale ranging from 0 to 100. Higher scores indicate greater treatment satisfaction.

    Time frame: baseline (day 1 of core phase), month 12 and 24

  13. Change From Baseline in Physician's Treatment Satisfaction

    Physician's treatment satisfaction was assessed using the physician's treatment satisfaction scale which is designed to rate 4 aspects of treatment (efficacy, safety, mode of administration, and overall satisfaction), each on a scale ranging from 1 (extremely satisfied) to 7 (extremely dissatisfied).

    Time frame: baseline (day 1 of core phase), month 12 and 24

07

Results

Posted Feb 18, 2015

Participant flow

Whole Intent-to-Treat
Participant flow — Whole Intent-to-Treat
MilestonePaliperidone PalmitateOral Antipsychotics
Started376388
Completed352363
Not completed2425
Withdrew: Missing responder assessment1012
Withdrew: Stopped; non-responder after 2 weeks66
Withdrew: Deviation; non-responder after 2 weeks67
Withdrew: Responder after 2 weeks, but stopped20
CORE Intent-To-Treat
Participant flow — CORE Intent-To-Treat
MilestonePaliperidone PalmitateOral Antipsychotics
Started352363
Completed272266
Not completed8097
Withdrew: Adverse event1411
Withdrew: Death11
Withdrew: Lack of efficacy26
Withdrew: Lost to follow-up45
Withdrew: Pregnancy10
Withdrew: Withdrawal by subject5260
Withdrew: Noncompliance with study drug05
Withdrew: Other01
Withdrew: Ineligibility34
Withdrew: Visit schedule issues12
Withdrew: Patient moved22

Outcome measures

PrimaryTime to First Relapse Event

Number of days from baseline (day 1 of core phase) to relapse as evaluated according the Csernansky criteria. A patient was considered to have relapsed if they met one or more of the following criteria: (1) psychiatric hospitalization; (2) an increase in the level of psychiatric care and an increase of 25 percent (%) from baseline in the Positive And Negative Syndrome Score (PANSS) total score (or an increase of 10 points if the baseline score was 40 or less); (3) deliberate self-injury; (4) suicidal or homicidal ideation that was clinically significant in the investigator's judgment; (5) violent behavior resulting in clinically significant injury to another person or property damage; (6) substantial clinical deterioration, defined as a change score of 6 ("much worse") or 7 ("very much worse") on the Clinical Global Impressions Scale (CGI-C); and/or (7) the required dose of the antipsychotic exceeds the maximum approved dose.

Time frame:
from baseline (Day 1 of core phase) up to maximally 24 months.
Reported as:
Mean · days
Time to First Relapse Event
daysPaliperidone PalmitateOral Antipsychotics
Time to First Relapse Event616 ± 10.9603 ± 13.1
Statistical analysis
  • Paliperidone Palmitate vs Oral Antipsychotics · Log Rank · p = 0.0191
SecondaryPercentage of Treatment Responders

The proportion of patients achieving a treatment response, defined as a ≥30% decrease (i.e., improvement) in Positive and Negative Syndrome Scale (PANSS) total score from baseline to endpoint. The PANSS is a 30-item scale (Range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate increased severity of schizophrenia symptoms.

Time frame:
from baseline (day 1 of core phase) up to maximally 24 months
Reported as:
Number · percentage of participants
Percentage of Treatment Responders
percentage of participantsPaliperidone PalmitateOral Antipsychotics
Percentage of Treatment Responders75.6 (70.8 to 79.8)69.4 (64.5 to 73.9)
SecondaryChange From Baseline in PANSS Total Score

Change from baseline in the PANSS: The PANSS is a 30-item scale (Range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.

Time frame:
Baseline, day 8, month 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, 24
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Total Score
units on a scalePaliperidone PalmitateOral Antipsychotics
Baseline score82.5 ± 12.0381.5 ± 11.70
change from baseline at Day 8-4.8 ± 5.93-3.7 ± 7.04
change from baseline at Month 1-9.4 ± 10.91-8.8 ± 10.15
change from baseline at Month 2-12.2 ± 12.19-12.3 ± 11.34
change from baseline at Month 3-14.5 ± 11.72-15.0 ± 11.15
change from baseline at Month 4-16.2 ± 13.03-16.8 ± 12.34
change from baseline at Month 6-18.5 ± 13.67-18.6 ± 13.09
change from baseline at Month 9-19.5 ± 14.72-20.1 ± 14.35
change from baseline at Month 12-21.8 ± 13.32-21.2 ± 14.45
change from baseline at Month 15-21.7 ± 14.56-21.9 ± 14.18
change from baseline at Month 18-23.5 ± 13.56-22.8 ± 14.41
change from baseline at Month 21-24.3 ± 13.60-23.7 ± 14.66
change from baseline at Month 24-25.5 ± 14.42-24.6 ± 14.16
change at Endpoint (LOCF)-16.6 ± 21.42-14.1 ± 21.29
SecondaryChange From Baseline in PANSS Subscale Score

Change from baseline in positive symptom, negative symptom and general psychopathology subscales of the PANSS scale. The PANSS scale is designed to assess symptoms of schizophrenia by means of the 30-items. The PANSS scale provides subscores for 3 subscales, that is, the positive symptoms subscale (7 items, range 7-49), the negative symptoms subscale (7 items, range 7-49), and the general psychopathology subscale (16 items, range 16-112). Each item of the scale is to be scored on a scale of 1 (absent) to 7 (extreme). Higher scores indicate higher severity of schizophrenia symptoms.

Time frame:
Baseline (day 1 of core phase), day 8, month 12, 24
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Subscale Score
units on a scalePaliperidone PalmitateOral Antipsychotics
Positive Subscale; Baseline score18.4 ± 3.9718.3 ± 4.01
Positive Subscale; change at Day 8-1.5 ± 2.11-1.3 ± 2.36
Positive Subscale; change at Month 12-6.3 ± 4.10-6.2 ± 4.35
Positive Subscale; change at Month 24-6.8 ± 4.39-6.7 ± 4.48
Positive Subscale; change at Endpoint (LOCF)-4.4 ± 6.61-3.8 ± 6.72
Negative Subscale; Baseline score22.6 ± 4.5522.3 ± 4.58
Negative Subscale; change at Day 8-1.0 ± 1.90-0.8 ± 2.10
Negative Subscale; change at Month 12-4.8 ± 4.69-4.7 ± 4.80
Negative Subscale; change at Month 24-6.2 ± 5.19-5.9 ± 4.74
Negative Subscale; change at Endpoint (LOCF)-4.1 ± 6.13-3.7 ± 5.79
General Psychopathology; Baseline score41.4 ± 6.7340.8 ± 6.59
General Psychopathology; change at Day 8-2.3 ± 3.58-1.6 ± 4.01
General Psychopathology; change at Month 12-10.7 ± 7.19-10.3 ± 7.64
General Psychopathology; change at Month 24-12.5 ± 7.63-12.0 ± 7.82
General Psychopathology; change at Endpoint (LOCF)-8.1 ± 10.96-6.7 ± 11.12
SecondaryChange From Baseline in PANSS Marder Factor Scores

Change from baseline in schizophrenia symptoms were assessed through the following PANSS factor scores as described by Marder: (1) positive symptoms (range 8-56): sum of delusions, hallucinatory behavior, grandiosity, suspiciousness, stereotyped thinking, somatic concern, unusual thought content, lack of judgment and insight; (2) negative symptoms (range 7-49): sum of blunted affect, emotional withdrawal, poor rapport, passive social withdrawal, lack of spontaneity, motor retardation, and active social avoidance; (3) disorganized thoughts (range 7-49): sum of conceptual disorganization, difficulty in abstract thinking, mannerisms and posturing, disorientation, poor attention, disturbance of volition, and preoccupation; (4) uncontrolled hostility/excitement (range 4-28): sum of excitement, hostility, uncooperativeness and poor impulse control; (5) anxiety/depression (range 4-28): sum of anxiety, guilt feelings, tension, and depression. Higher scores indicate higher severity of symptoms

Time frame:
Baseline (day 1 of core phase), day 8, month 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Marder Factor Scores
units on a scalePaliperidone PalmitateOral Antipsychotics
Positive Symptoms Factor Score; Baseline score22.9 ± 4.2622.5 ± 4.39
Positive Symptoms Factor Score; change at Day 8-1.5 ± 2.22-1.3 ± 2.50
Positive Symptoms Factor Score; change at Month 12-6.9 ± 4.31-6.9 ± 4.76
Positive Symptoms Factor Score; change at Month 24-7.6 ± 4.48-7.8 ± 4.95
Positive Symptoms Factor Score; change at Endpoint-5.0 ± 6.73-4.7 ± 6.80
Negative Symptoms Factor Score; Baseline score22.0 ± 4.6521.5 ± 4.95
Negative Symptoms Factor Score; change at Day 8-1.0 ± 1.93-0.8 ± 2.25
Negative Symptoms Factor Score; change at Month 12-5.1 ± 4.73-4.9 ± 4.88
Negative Symptoms Factor Score; change at Month 24-6.5 ± 5.16-6.1 ± 5.05
Negative Symptoms Factor Score; change at Endpoint-4.3 ± 6.26-3.8 ± 6.08
Disorganized Thoughts Factor; Baseline score19.5 ± 3.5419.4 ± 3.41
Disorganized Thoughts Factor; change at Day 8-1.0 ± 1.61-0.6 ± 2.06
Disorganized Thoughts Factor; change at Month 12-4.6 ± 3.42-4.6 ± 3.78
Disorganized Thoughts Factor; change at Month 24-5.4 ± 3.90-5.4 ± 3.82
Disorganized Thoughts Factor; change at Endpoint-3.7 ± 5.03-3.2 ± 5.16
Uncontrolled Hostility/Excitement; Baseline score8.4 ± 2.718.3 ± 2.64
Uncontrolled Hostility/Excitement; change at Day 8-0.7 ± 1.60-0.4 ± 1.47
Uncontrolled Hostility/Excitement; change Month 12-2.3 ± 2.57-2.1 ± 2.62
Uncontrolled Hostility/Excitement; change Month 24-2.7 ± 2.77-2.3 ± 2.73
Uncontrolled Hostility/Excitement; change Endpoint-1.5 ± 3.82-0.8 ± 3.87
Anxiety/Depression Factor; Baseline score9.7 ± 2.749.8 ± 2.85
Anxiety/Depression Factor; change at Day 8-0.8 ± 1.57-0.6 ± 1.72
Anxiety/Depression Factor; change at Month 12-2.8 ± 2.67-2.7 ± 2.56
Anxiety/Depression Factor; change at Month 24-3.3 ± 2.90-3.0 ± 2.78
Anxiety/Depression Factor; change at Endpoint-2.1 ± 3.51-1.8 ± 3.47
SecondaryChange From Baseline in Clinical Global Impression Severity (CGI-S) Score

The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global clinical assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate higher impression of illness severity.

Time frame:
Baseline (day 1 of core phase), day 8, month 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, 24
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression Severity (CGI-S) Score
units on a scalePaliperidone PalmitateOral Antipsychotics
Baseline score3.9 ± 0.373.8 ± 0.40
change from baseline at Day 8-0.1 ± 0.38-0.1 ± 0.43
change from baseline at Month 1-0.3 ± 0.61-0.3 ± 0.61
change from baseline at Month 2-0.4 ± 0.70-0.5 ± 0.71
change from baseline at Month 3-0.6 ± 0.69-0.6 ± 0.69
change from baseline at Month 4-0.7 ± 0.75-0.8 ± 0.71
change from baseline at Month 6-0.8 ± 0.78-0.8 ± 0.73
change from baseline at Month 9-0.9 ± 0.80-0.9 ± 0.78
change from baseline at Month 12-1.0 ± 0.78-1.0 ± 0.80
change from baseline at Month 15-0.9 ± 0.82-1.0 ± 0.80
change from baseline at Month 18-1.0 ± 0.80-1.0 ± 0.78
change from baseline at Month 21-1.0 ± 0.78-1.1 ± 0.82
change from baseline at Month 24-1.1 ± 0.79-1.1 ± 0.80
change from baseline at Endpoint (LOCF)-0.7 ± 1.14-0.6 ± 1.12
SecondaryClinical Global Impression-Change (CGI-C)

The Clinical Global Impression-Change (CGI-C) rating scale is used to rate the change in severity of the patient's illness compared to baseline (day 1 of core phase) on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Month 24 and endpoint
Reported as:
Number · percentage of participants
Clinical Global Impression-Change (CGI-C)
percentage of participantsPaliperidone PalmitateOral Antipsychotics
Month 24; Very Much Improved22.9 ± 22.921.7 ± 21.7
Month 24; Much Improved52.9 ± 52.947.8 ± 47.8
Month 24; Minimally Improved17.0 ± 17.020.8 ± 20.8
Month 24; No change6.7 ± 6.77.7 ± 7.7
Month 24; Minimally Worse0.0 ± 0.01.0 ± 1.0
Month 24; Much Worse0.4 ± 0.41.0 ± 1.0
Month 24; Very Much Worse0.0 ± 0.00.0 ± 0.0
Endpoint; Very Much Improved17.1 ± 17.114.2 ± 14.2
Endpoint; Much Improved40.6 ± 40.635.8 ± 35.8
Endpoint; Minimally Improved17.4 ± 17.421.9 ± 21.9
Endpoint; No change10.6 ± 10.610.8 ± 10.8
Endpoint; Minimally Worse5.1 ± 5.16.1 ± 6.1
Endpoint; Much Worse9.1 ± 9.110.6 ± 10.6
Endpoint; Very Much Worse0.0 ± 0.00.6 ± 0.6
SecondaryChanges From Baseline in Personal and Social Performance (PSP) Total Score

The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

Time frame:
baseline (day 1 of core phase), month 1, 3, 6, 9, 12, 15, 18, 21 and 24
Reported as:
Mean · units on a scale
Changes From Baseline in Personal and Social Performance (PSP) Total Score
units on a scalePaliperidone PalmitateOral Antipsychotics
Baseline score55.3 ± 11.3155.3 ± 11.07
change from baseline at Month 14.9 ± 7.784.3 ± 7.65
change from baseline at Month 37.6 ± 8.917.7 ± 9.02
change from baseline at Month 69.9 ± 10.0810.8 ± 10.32
change from baseline at Month 911.4 ± 11.2811.9 ± 11.03
change from baseline at Month 1212.7 ± 10.7812.3 ± 11.27
change from baseline at Month 1512.9 ± 11.0512.9 ± 10.82
change from baseline at Month 1814.0 ± 11.4413.3 ± 11.44
change from baseline at Month 2114.7 ± 12.314.0 ± 11.69
change from baseline at Month 2415.2 ± 12.7214.6 ± 11.72
change from baseline at Endpoint (LOCF)9.8 ± 15.418.7 ± 14.89
SecondaryChange From Baseline in Short Form-36 Health Survey (SF-36)

The Short Form-36 Health Survey (SF-36) is a measure of Participant-reported health status. It is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Two summary scale scores are computed based on weighted combinations of the 8 subscale scores: the Physical Component Summary and the Mental Component Summary. Each summary scale score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status.

Time frame:
baseline (day 1 of core phase), month 6, 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Short Form-36 Health Survey (SF-36)
units on a scalePaliperidone PalmitateOral Antipsychotics
Physical Component, Baseline score50.3 ± 8.0450.6 ± 7.83
Physical Component, change at Month 61.2 ± 6.921.3 ± 6.52
Physical Component, change at Month 121.6 ± 7.621.2 ± 7.08
Physical Component, change at Month 242.2 ± 8.402.1 ± 6.74
Physical Component, change at Endpoint (LOCF)1.7 ± 8.521.4 ± 7.40
Mental Component, Baseline score32.1 ± 12.6231.4 ± 12.92
Mental Component, change at Month 68.2 ± 11.589.1 ± 12.43
Mental Component, change at Month 1210.5 ± 11.7511.6 ± 12.77
Mental Component, change at Month 2412.0 ± 13.3412.3 ± 12.83
Mental Component, change at Endpoint (LOCF)9.0 ± 14.998.7 ± 14.37
SecondaryChange From Baseline in EuroQol 5-Dimensional Questionnaire (EQ-5D) VAS Score

The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analog scale, with 0 representing the worst imaginable health state and 100 representing the best imaginable health state. The EQ VAS is used as a quantitative measure of health outcome as judged by the individual respondent.

Time frame:
baseline (day 1 of core phase), month 6, 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol 5-Dimensional Questionnaire (EQ-5D) VAS Score
units on a scalePaliperidone PalmitateOral Antipsychotics
Baseline score57.5 ± 20.9457.6 ± 20.41
change from baseline at Month 610.6 ± 17.3111.9 ± 17.00
change from baseline at Month 1215.0 ± 17.3815.6 ± 18.32
change from baseline at Month 2417.9 ± 19.4818.6 ± 17.36
change from baseline at Endpoint (LOCF)13.0 ± 22.8711.9 ± 21.54
SecondaryChange From Baseline in EuroQol 5-Dimensional Questionnaire (EQ-5D) Index Score

The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. A higher score indicates an improvement in health in the Health Status Index.

Time frame:
baseline (day 1 of core phase), month 6, 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol 5-Dimensional Questionnaire (EQ-5D) Index Score
units on a scalePaliperidone PalmitateOral Antipsychotics
Baseline score0.80 ± 0.1730.78 ± 0.181
change from baseline at Month 60.06 ± 0.1810.09 ± 0.157
change from baseline at Month 120.08 ± 0.1850.11 ± 0.179
change from baseline at Month 240.10 ± 0.2010.12 ± 0.161
change from baseline at Endpoint (LOCF)0.06 ± 0.2240.08 ± 0.192
SecondaryChange From Baseline in Subjective Well-Being Under Neuroleptics-Short Form (SWN-S) Total Score

The SWN-S is a patient self-rated scale developed to measure the subjective well-being for the previous 7 days of a patient under neuroleptic treatment. The SWN-S consists of 20 items (each item is rated from 1=not at all to 6=very much). The total score ranges from 20 to 120 with higher score indicating greater subjective well-being.

Time frame:
baseline (day 1 of core phase), month 6, 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Subjective Well-Being Under Neuroleptics-Short Form (SWN-S) Total Score
units on a scalePaliperidone PalmitateOral Antipsychotics
Baseline score76.5 ± 17.0276.7 ± 17.07
change from baseline at Month 68.4 ± 14.069.1 ± 14.40
change from baseline at Month 1211.4 ± 15.8111.1 ± 17.02
change from baseline at Month 2413.4 ± 18.1413.1 ± 15.76
change from baseline at Endpoint (LOCF)9.7 ± 19.178.3 ± 17.58
SecondaryChange From Baseline in Patient's Treatment Satisfaction

Patient's satisfaction with medication was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM is divided into 4 subscales (effectiveness, side effects, convenience, and global satisfaction), with the value of each subscale ranging from 0 to 100. Higher scores indicate greater treatment satisfaction.

Time frame:
baseline (day 1 of core phase), month 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Patient's Treatment Satisfaction
units on a scalePaliperidone PalmitateOral Antipsychotics
Effectiveness; Baseline score61.9 ± 16.9759.5 ± 16.82
Effectiveness; change at Month 126.7 ± 22.726.6 ± 21.99
Effectiveness; change at Month 248.5 ± 21.7512.4 ± 20.69
Effectiveness; change at Endpoint (LOCF)3.8 ± 23.474.5 ± 25.31
Side-effects; Baseline score91.3 ± 19.7487.3 ± 23.41
Side-effects; change at Month 122.1 ± 22.712.5 ± 25.66
Side-effects; change at Month 242.8 ± 20.933.5 ± 23.96
Side-effects; change at Endpoint (LOCF)-1.4 ± 25.590.7 ± 28.24
Convenience; Baseline score67.1 ± 16.6668.4 ± 16.45
Convenience; change at Month 128.4 ± 19.101.0 ± 17.79
Convenience; change at Month 2410.4 ± 20.494.7 ± 17.69
Convenience; change at Endpoint (LOCF)7.4 ± 21.240.3 ± 21.68
Global Satisfaction; Baseline score64.0 ± 18.1362.8 ± 18.31
Global Satisfaction; change at Month 128.2 ± 18.897.0 ± 21.18
Global Satisfaction; change at Month 248.6 ± 21.069.2 ± 20.39
Global Satisfaction; change at Endpoint (LOCF)3.0 ± 25.011.0 ± 26.76
SecondaryChange From Baseline in Physician's Treatment Satisfaction

Physician's treatment satisfaction was assessed using the physician's treatment satisfaction scale which is designed to rate 4 aspects of treatment (efficacy, safety, mode of administration, and overall satisfaction), each on a scale ranging from 1 (extremely satisfied) to 7 (extremely dissatisfied).

Time frame:
baseline (day 1 of core phase), month 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Physician's Treatment Satisfaction
units on a scalePaliperidone PalmitateOral Antipsychotics
Efficacy; Baseline score2.7 ± 0.792.8 ± 0.79
Efficacy; change at Month 12-0.5 ± 1.03-0.4 ± 0.92
Efficacy; change at Month 24-0.6 ± 1.10-0.6 ± 0.98
Efficacy; change at Endpoint (LOCF)-0.2 ± 1.460.0 ± 1.43
Safety; Baseline score2.4 ± 0.802.6 ± 0.77
Safety; change at Month 12-0.4 ± 0.97-0.2 ± 0.90
Safety; change at Month 24-0.4 ± 0.97-0.3 ± 1.04
Safety; change at Endpoint (LOCF)-0.2 ± 1.19-0.0 ± 1.18
Mode of Administration: Baseline score2.6 ± 0.862.6 ± 0.83
Mode of Administration: change at Month 12-0.7 ± 1.02-0.0 ± 0.92
Mode of Administration: change at Month 24-0.7 ± 1.09-0.1 ± 0.92
Mode of Administration: change at Endpoint (LOCF)-0.5 ± 1.160.0 ± 1.04
Overall Satisfaction; Baseline score2.6 ± 0.782.7 ± 0.74
Overall Satisfaction; change at Month 12-0.5 ± 0.95-0.3 ± 0.84
Overall Satisfaction; change at Month 24-0.6 ± 1.00-0.3 ± 0.86
Overall Satisfaction; change at Endpoint (LOCF)-0.2 ± 1.250.1 ± 1.16
PrimaryNumber of Participants With a Relapse Event

Number of participants with a relapse event with relapses evaluated according the Csernansky criteria. A patient was considered to have relapsed if they met one or more of the following criteria: (1) psychiatric hospitalization; (2) an increase in the level of psychiatric care and an increase of 25% from baseline in the PANSS total score (or an increase of 10 points if the baseline score was 40 or less); (3) deliberate self-injury; (4) suicidal or homicidal ideation that was clinically significant in the investigator's judgment; (5) violent behavior resulting in clinically significant injury to another person or property damage; (6) substantial clinical deterioration, defined as a change score of 6 ("much worse") or 7 ("very much worse") on the Clinical Global Impressions Scale (CGI-C); and/or (7) the required dose of the antipsychotic exceeds the maximum approved dose.

Time frame:
from baseline (Day 1 of core phase) up to maximally 24 months
Reported as:
Number · number of participants
Number of Participants With a Relapse Event
number of participantsPaliperidone PalmitateOral Antipsychotics
No300287
Yes5276
Statistical analysis
  • Paliperidone Palmitate vs Oral Antipsychotics · Fisher Exact · p = 0.0323

Adverse events

Collected over from randomization until maximally month 24. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone Palmitate—42/376 (11.2%)208/376 (55.3%)
Oral Antipsychotics—48/388 (12.4%)208/388 (53.6%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventPaliperidone PalmitateOral Antipsychotics
SchizophreniaPsychiatric disorders21/37622/388
Psychotic disorderPsychiatric disorders7/3768/388
Schizophrenia, paranoid typePsychiatric disorders3/3764/388
AnxietyPsychiatric disorders2/3760/388
AgitationPsychiatric disorders1/3762/388
Alcohol abusePsychiatric disorders0/3762/388
Suicide attemptPsychiatric disorders0/3762/388
Cardiac arrestCardiac disorders1/3760/388
Abdominal painGastrointestinal disorders1/3760/388
Cholecystitis chronicHepatobiliary disorders1/3760/388
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPaliperidone PalmitateOral Antipsychotics
Weight increasedInvestigations58/37665/388
InsomniaPsychiatric disorders42/37639/388
HeadacheNervous system disorders40/37634/388
NasopharyngitisInfections and infestations25/37620/388
Injection site painGeneral disorders24/3760/388
AnxietyPsychiatric disorders22/37623/388
Suicidal ideationPsychiatric disorders20/37623/388
TremorNervous system disorders22/37617/388
AkathisiaNervous system disorders21/37622/388
SomnolenceNervous system disorders13/37622/388

Baseline characteristics

Whole Intent-to-Treat population: All randomized patients who received at least 1 dose of study medication during the screening or treatment phase

Age, Continuous
Age, Continuous(years)Paliperidone PalmitateOral AntipsychoticsTotal
Mean32.5 ± 10.7332.4 ± 1032.5 ± 10.36
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone PalmitateOral AntipsychoticsTotal
Female147171318
Male229217446
Region of Enrollment
Region of Enrollment(participants)Paliperidone PalmitateOral AntipsychoticsTotal
AUSTRIA011
BELGIUM7512
BULGARIA151530
CROATIA121224
CZECH REPUBLIC142135
EGYPT161430
ESTONIA235
FRANCE448
GERMANY325
HUNGARY151631
ISRAEL6511
ITALY101121
JORDAN151126
KOREA, REPUBLIC OF KOREA246
LITHUANIA131427
POLAND111122
ROMANIA131427
RUSSIAN FEDERATION9090180
SLOVAKIA131427
SOUTH AFRICA262450
SPAIN347
TAIWAN, PROVINCE OF CHINA459
TURKEY11920
UKRAINE7179150
08

Study locations

99 sites
  • Wien, Austria
  • Bertrix, Belgium
  • Gent, Belgium
  • Liège, Belgium
  • Oostende, Belgium
  • Bourgas, Bulgaria
  • Plovdiv N/A, Bulgaria
  • Radnevo N/A, Bulgaria
  • Zagreb, Croatia
  • Brno, Czech Republic
  • Litomerice, Czech Republic
  • Olomouc 9, Czech Republic
  • Praha 10, Czech Republic
  • Praha, Czech Republic
  • Prerov, Czech Republic
  • Alexandria, Egypt
  • Cairo, Egypt
  • Talinn, Estonia
  • Tartu N/A, Estonia
  • Colombes Cedex, France
  • La Seyne Sur Mer, France
  • Limoges N/A, France
  • Metz Cedex 01, France
  • Paris, France
  • Saint Avé, France
  • Berlin, Germany
  • Bochum, Germany
  • Mannheim, Germany
  • Munchen, Germany
  • München, Germany
  • Thessalonikis, Greece
  • Budapest, Hungary
  • Kalocsa, Hungary
  • Nagykallo, Hungary
  • Sopron, Hungary
  • Bat-Yam, Israel
  • Beer Yaakov, Israel
  • Hod-Hasharon, Israel
  • Ramat-Gan, Israel
  • Tirat Hacarmel, Israel
  • Amman, Jordan
  • Goyang, Korea, Republic of
  • Incheon, Korea, Republic of
  • Kyounggi, Korea, Republic of
  • Seoul, Korea, Republic of
  • Siauliai, Lithuania
  • Vilnius, Lithuania
  • Chelmno, Poland
  • Gdansk, Poland
  • Torun N/A, Poland
  • Zabki, Poland
  • Arad, Romania
  • Bucharest, Romania
  • Jebel, Romania
  • Oradea, Romania
  • Sibiu, Romania
  • Ekaterinburg Na, Russian Federation
  • Krasnodar N/A, Russian Federation
  • Nizny Novgorod, Russian Federation
  • Samara, Russian Federation
  • Saratov, Russian Federation
  • St Petersburg N/A, Russian Federation
  • St Petersburg, Russian Federation
  • St-Petersburg, Russian Federation
  • Tomsk, Russian Federation
  • Yaroslavl, Russian Federation
  • Bratislava, Slovakia
  • Michalovce, Slovakia
  • Rimavska Sobota, Slovakia
  • Cape Town, South Africa
  • Pretoria, South Africa
  • Barcelona, Spain
  • Burgos, Spain
  • Elche, Spain
  • Madrid, Spain
  • Sant Boi De Llobregat, Spain
  • Zamora, Spain
  • Taichung, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan
  • Istanbul, Turkey
  • Manisa Turkey, Turkey
  • Zonguldak, Turkey
  • Dnipropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Glevakha, Ukraine
  • Kharkiv, Ukraine
  • Kharkov, Ukraine
  • Kherson, Ukraine
  • Kiev, Ukraine
  • Lviv, Ukraine
  • Odessa, Ukraine
  • Poltava, Ukraine
  • Simferopol, Ukraine
  • Uzhgorod, Ukraine
  • Birmingham, United Kingdom
  • Exeter, United Kingdom
  • London, United Kingdom
  • Warrington, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2010
First posted
Mar 5, 2010
Start
Feb 2010
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Feb 18, 2015
Last update
Feb 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01081769
Responsible party
Sponsor
First posted
Mar 5, 2010
Start date
Feb 2010
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Feb 18, 2015
Last update
Feb 18, 2015

Study contacts

Janssen-Cilag International NV Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion